Compare · BLI vs DFTX
BLI vs DFTX
Side-by-side comparison of Berkeley Lights Inc. (BLI) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLI and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.92B, about 8.3x BLI ($591.8M).
- DFTX has hit the wire 7 times in the past 4 weeks while BLI has been quiet.
- BLI has more recent analyst coverage (13 ratings vs 5 for DFTX).
- Company
- Berkeley Lights Inc.
- Definium Therapeutics Inc.
- Price
- $1.19-6.67%
- $43.90-2.52%
- Market cap
- $591.8M
- $4.92B
- 1M return
- -
- +19.75%
- 1Y return
- -
- +355.65%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 0
- 7
- Recent ratings
- 13
- 5
BLI
Berkeley Lights Inc.
Berkeley Lights, Inc., a digital cell biology company, focuses on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. The company offers an integrated platform, which comprise of proprietary consumables, including OptoSelect chips and reagent kits, automation systems, and application and workflow software. It serves in North America, the Asia Pacific, and Europe. The company was incorporated in 2011 and is headquartered in Emeryville, California.
Latest BLI
- Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
- SEC Form SC 13G/A filed by Berkeley Lights Inc. (Amendment)
- SEC Form 15-12G filed by Berkeley Lights Inc.
- Kadia Siddhartha returned 1,240,689 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chiminski John R returned 112,465 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Silvester Peter returned 64,596 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Hopfield Jessica returned 105,207 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Joshi Mehul returned 65,013 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Hobbs Eric returned 244,816 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Moritz Michael J returned 1,451,925 shares to the company (SEC Form 4)
Latest DFTX
- A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
- Definium Therapeutics Announces New Employee Inducement Grants
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
- New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
- Definium Therapeutics Announces New Employee Inducement Grants
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Chief Legal Officer Sullivan Mark sold $585,750 worth of shares (13,008 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 320,571 units (SEC Form 4) (withholding tax)
- Chief Medical Officer Karlin Daniel sold $451,876 worth of shares (10,035 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 503,282 units (SEC Form 4) (withholding obligation)
- Chief Financial Officer Roberts Brandi sold $135,675 worth of shares (3,013 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 209,487 units (SEC Form 4) (withholding obligation)